Meda: Interim Report, January -- March 2005
02 mai 2005 10h29 HE
|
Meda
STOCKHOLM, Sweden, May 02, 2005 (PRIMEZONE) --
First quarter 2005
Acquisition of Cibacen and Cibadrex, pharmaceuticals from Novartis, enhanced sales and profit.
-- Group sales jumped 45%...
Meda acquires Cyklokapron and Cyklo-F
02 juil. 2004 10h21 HE
|
Meda
STOCKHOLM, Sweden, July 2, 2004 (PRIMEZONE) -- Meda has signed an agreement with the Belgian pharmaceuticals company Omega Pharma to acquire the European rights to the tablet formulations of the...
Meda Acquires Product from the American Pharmaceutical Company Lilly
16 avr. 2003 06h02 HE
|
Meda
STOCKHOLM, Sweden, April 16, 2003 (PRIMEZONE) -- Meda (Other OTC:MDABF) (Stockholm:MEDAa) announces that the company has acquired the rights in the U.K. and Sweden to the well-known analgesic drug...
Meda Acquires Rights to Colifoam, Proctofoam and Epifoam from GlaxoSmithKline
18 nov. 2002 08h06 HE
|
Meda
STOCKHOLM, Sweden, Nov. 18, 2002 (PRIMEZONE) -- Meda AB (Other OTC:MDABF) (Stockholm:MEDAa), the Swedish Specialty Pharmaceutical Company, has agreed to a deal with the GlaxoSmithKline Group (GSK) on...
Meda in Deal with Two American Companies
12 sept. 2002 08h12 HE
|
Meda
STOCKHOLM, Sweden, Sept. 12, 2002 (PRIMEZONE) -- Meda has signed a long-term license agreement with Vivus for the exclusive marketing rights of MUSE(R) (alprostadil) in Europe. VIVUS markets MUSE in...
Meda Acquires Patent Rights from Karolinska Innovation AB
01 juil. 2002 04h37 HE
|
Meda
STOCKHOLM, Sweden, July 01, 2002 (PRIMEZONE) -- Meda has signed an agreement with Karolinska Innovation AB regarding acquisition of patents based upon Professor Lars Burmans discovery that the toxin...
Meda Strengthens the Product Portfolio Within Pain and Inflammatory
19 juin 2002 08h38 HE
|
Meda
STOCKHOLM, Sweden, June 19, 2002 (PRIMEZONE) -- Meda has signed a long-term license agreement with the pharmaceutical company Tedec-Meiji concerning the exclusive rights to the product Adant...
Meda Signs Long Term Strategic Agreement with Ranbaxy
22 mai 2002 04h45 HE
|
Meda
STOCKHOLM, Sweden, May 22, 2002 (PRIMEZONE) -- Meda has entered into a long-term strategic agreement with India's largest pharmaceutical company, Ranbaxy Laboratories Limited, regarding generic...
Meda Signs Long-Term License Agreement Concerning Zanidip--lercanidipin
12 févr. 2002 04h59 HE
|
Meda
STOCKHOLM, Sweden, Feb. 12, 2002 (PRIMEZONE) -- Meda has concluded a long-term license agreement with the European pharmaceuticals group Recordati on sole marketing rights to Zanidip (lercanidipin)...